BCDA on Nasdaq
BioCardia, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Inmune Bio, Inc., EXOZYMES INC. or Calidi Biotherapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Collaboration agreement revenue | $0 | $58.0K |
| Research and development | $5.0M | $4.4M |
| Selling, general and administrative | $3.3M | $3.7M |
| Total costs and expenses | $8.3M | $8.1M |
| Operating loss | -$8.3M | -$8.0M |
| Total other income, net | $50.0K | $55.0K |
| Net loss | -$8.2M | -$7.9M |
| Net loss per share, basic and diluted (in dollars per share) | -$1.23 | -$2.90 |
| Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | 6.7M shares | 2.7M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $2.5M | $2.4M | |
| Accounts receivable, net of allowance for doubtful accounts of $0 and $0 as of December 31, 2025 and 2024, respectively | $20.0K | $0 | |
| Prepaid expenses | $216.0K | $251.0K | |
| Total current assets | $2.7M | $2.6M | |
| Property and equipment, net | $16.0K | $33.0K | |
| Operating lease right-of-use asset, net | $494.0K | $898.0K | |
| Other assets | $171.0K | $171.0K | |
| Total assets | $3.4M | $3.7M | |
| Accounts payable | $641.0K | $385.0K | |
| Accrued expenses and other current liabilities | $1.3M | $1.6M | |
| Operating lease liability - current | $442.0K | $385.0K | |
| Total current liabilities | $2.4M | $2.3M | |
| Operating lease liability - noncurrent | $86.0K | $566.0K | |
| Total liabilities | $2.5M | $2.9M | |
| Preferred stock, $0.001 par value, 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.001 par value, 50,000,000 shares authorized, 10,755,647 and 4,600,910 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $11.0K | $5.0K | |
| Additional paid-in capital | $169.2M | $161.0M | |
| Accumulated deficit | -$168.3M | -$160.1M | |
| Total stockholders equity | $895.0K | $837.0K | -$1.6M |
| Total liabilities and stockholders equity | $3.4M | $3.7M | |
| Accounts Receivable, Allowance for Credit Loss, Current | $0 | $0 | |
| Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $0.00 | $0.00 | |
| Preferred Stock, Shares Authorized (in shares) | 25.0M shares | 25.0M shares | |
| Preferred Stock, Shares Issued (in shares) | 0 shares | 0 shares | |
| Preferred Stock, Shares Outstanding (in shares) | 0 shares | 0 shares | |
| Common Stock, Par or Stated Value Per Share (in dollars per share) | $0.00 | $0.00 | |
| Common Stock, Shares Authorized (in shares) | 50.0M shares | 50.0M shares | |
| Common Stock, Shares, Issued (in shares) | 10.8M shares | 4.6M shares | |
| Common Stock, Shares, Outstanding (in shares) | 10.8M shares | 4.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$8.2M | -$7.9M |
| Depreciation | $24.0K | $67.0K |
| Reduction in the carrying amount of right-of-use assets | $481.0K | $482.0K |
| Share-based compensation | $430.0K | $741.0K |
| Allowance for doubtful accounts | $0 | -$34.0K |
| Accounts receivable | $20.0K | -$97.0K |
| Prepaid expenses | $35.0K | $44.0K |
| Accounts payable | $163.0K | -$316.0K |
| Accrued expenses and other current liabilities | $179.0K | -$538.0K |
| Operating lease liability | -$500.0K | -$483.0K |
| Net cash used in operating activities | -$7.4M | -$7.9M |
| Purchase of property and equipment | -$7.0K | -$6.0K |
| Net cash used in investing activities | -$7.0K | -$6.0K |
| Exercise of common stock warrants | $5.0K | $0 |
| Taxes paid related to net share settlement of equity awards | -$197.0K | -$140.0K |
| Proceeds from sales of common stock | $8.7M | $10.6M |
| Issuance costs of sale of common stock | -$930.0K | -$1.3M |
| Net cash provided by financing activities | $7.6M | $9.2M |
| Net change in cash and cash equivalents | $125.0K | $1.3M |
| Unpaid issuance costs of common stock | $99.0K | $6.0K |
| Restricted stock units issued to settle management bonus obligations | $184.0K | $156.0K |
Former names
Recent filings
- Oct 7, 20268-K
- Oct 1, 20268-K
- Sep 30, 20264
- Sep 23, 20268-K
- Sep 23, 20264
- Sep 21, 20268-K
- Sep 10, 20268-K
- Sep 4, 20264
- Aug 24, 20268-K
- Aug 21, 20268-K
- Aug 18, 20264
- Aug 13, 20264
- Aug 12, 202610-Q
- Aug 12, 20268-K
- Jul 29, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBioCardia, Inc. filings on SEC EDGAR
- 2SEC EDGARBioCardia, Inc. filings on SEC EDGAR
- 3SEC EDGARBioCardia, Inc. 10-K for fiscal 2025
- 4SEC EDGARBioCardia, Inc. 10-K for fiscal 2019
- 5SEC EDGARBioCardia, Inc. 10-K for fiscal 2020
- 6SEC EDGARBioCardia, Inc. 10-K for fiscal 2021
- 7SEC EDGARBioCardia, Inc. 10-K for fiscal 2022
- 8SEC EDGARBioCardia, Inc. 10-K for fiscal 2023
- 9SEC EDGARBioCardia, Inc. 10-Q for fiscal 2026
- 10SEC EDGARBioCardia, Inc. 10-Q for fiscal 2026